Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"BioCorRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Irisys to Manufacture BioCorRx's Opioid Use Disorder Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Engages IRISYS LLC as GMP Manufacturer for AS1411 Drug Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRISYS LLC Signs a Third Contract with TFF Pharma to Produce Medication to Treat Lung Conditions, Including COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"IRISYS, LLC Awarded $850,000 NIH Contract for the Formulation of Drinabant","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by IRISYS, LLC

    Menu

    IRISYS, LLC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              IRISYS, LLC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IRISYS, LLC Awarded $850,000 NIH Contract for the Formulation of Drinabant

              Details:

              IRISYS, has been awarded by the National Center for Advancing Translational Sciences (NCATS), one of 27 institutes of the NIH, to develop a new injectable formulation of Drinabant, a selective, high affinity cannabinoid receptor (CB-1) antagonist.

              Lead Product(s): Drinabant

              Therapeutic Area: Psychiatry/Psychology Product Name: OPNT004

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institutes of Health

              Deal Size: $0.8 million Upfront Cash: Undisclosed

              Deal Type: Funding January 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IRISYS, LLC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IRISYS LLC Signs a Third Contract with TFF Pharma to Produce Medication to Treat Lung Conditions, Including COVID-19

              Details:

              TFF Pharmaceuticals contracted with Irisys to manufacture an inhalable lung medication with the potential to treat COVID-19. IRISYS will be responsible for the initial production and testing of TFF’s investigational powder product for inhalation.

              Lead Product(s): Niclosamide

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: TFF Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership September 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IRISYS, LLC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Qualigen Therapeutics Engages IRISYS LLC as GMP Manufacturer for AS1411 Drug Product

              Details:

              Preclinical studies at the University of Louisville's (UofL) prestigious Center for Infectious Disease have demonstrated the ability of AS1411 to protect cells from the damaging effects of the novel coronavirus by binding to the nucleolin protein.

              Lead Product(s): AS1411

              Therapeutic Area: Infections and Infectious Diseases Product Name: AS1411

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Qualigen Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 31, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IRISYS, LLC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Irisys to Manufacture BioCorRx's Opioid Use Disorder Treatment

              Details:

              Irisys is providing contract development and GMP manufacturing services to BioCorRx Pharmaceuticals for a sterile naltrexone sub-cutaneous implant (BICX102) used in treatment of opioid use disorder and the prevention of relapse following opioid detoxification.

              Lead Product(s): Naltrexone

              Therapeutic Area: Psychiatry/Psychology Product Name: BICX102

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: BioCorRx

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership February 26, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY